Pharmacogenomics Market

7500+ companies worldwide approach us every year for their revenue growth initiatives
Global top 2000 strategist rely on us for their growth strategies.
80% of fortune 2000 companies rely on our research to identify new revenue sources.
30000 High Growth Opportunities
95% renewal rate
KNOW MORE
  1. HOME
  2. Top Market Reports
  3. Pharmacogenomics Market

Pharmacogenomics Market by Product & Service (Kits & Reagents), Technology (Sequencing, PCR, Microarray), Application (Drug Discovery, Clinical Research, Personalized Medicine), Disease Area (Cancer, Neurological, Cardiovascular) - Global Forecast to 2028

FREE BROCHURE FREE SAMPLE REPORT
Report Code: BT 8937 Feb, 2024, by marketsandmarkets.com

The global pharmacogenomics market in terms of revenue was estimated to be worth $3.5 Billion in 2023 and is poised to reach $5.8 Billion by 2028, growing at a CAGR of 10.6% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The expansion of the market is primarily propelled by a surge in genomic projects, augmented R&D investments, and the rising prevalence of cancer. Additionally, the substantial growth of pharmacogenomics in the past decade can be attributed to an intensified emphasis on translational research for drug discovery and development.

Pharmacogenomics Market- Global Forecast to 2028

Pharmacogenomics Market

To know about the assumptions considered for the study, Request for Free Sample Report

Attractive Opportunities in the Pharmacogenomics Market

Pharmacogenomics Market

Global Pharmacogenomics Market Dynamics

DRIVER: Growing prevalence of chronic and genetic diseases

The increasing incidence and prevalence of chronic and genetic diseases is a pivotal driving factor behind the burgeoning growth of the market. As diseases such as cancer, cardiovascular disorders, and diabetes become more prevalent, personalized medicine approaches facilitated by pharmacogenomics are gaining prominence. For instance, the rising number of cancer cases has led to a demand for tailored treatments based on individual genetic profiles, driving the adoption of pharmacogenomic strategies. According to World Health Organization estimates, worldwide, an estimated 20 million new cancer cases and 10 million cancer-related deaths occurred in 2020. Projections suggest a frightening 60% surge in the cancer burden within the next two decades, imposing greater strain on healthcare systems, individuals, and communities. This market growth is further fueled by the need for more effective and personalized therapeutic interventions in the face of a growing global health burden.

RESTRAINT: Concern related to drug response variability

The complexities associated with variabilities in drug responses pose substantial challenges to the progress of pharmacogenomics. Factors such as genetic elements, metabolism variations, and ethnic differences contribute to individualized responses, hindering accurate prediction and interpretation. The limited availability of drug-specific and gene-tailored pharmacogenomic tests impedes the comprehensive implementation of genotype-based drug stratification. Additionally, the complexity of interpreting genetic variants, establishing their clinical validity and utility, and integrating this knowledge into routine clinical practices creates obstacles for the widespread adoption of pharmacogenomics in healthcare. These challenges, rooted in the complexities of drug response variabilities, impede the broad utilization and integration of pharmacogenomics into standardized healthcare practices.

OPPORTUNITY: Utilization of genomics in personalized medicine

The utilization of genomics and pharmacogenomics in personalized medicine is a driving fueling the growth of the market. As healthcare increasingly shifts toward personalized treatment approaches, the ability to tailor medical interventions based on an individual's genetic makeup becomes crucial. Pharmacogenomic insights enable healthcare providers to predict how individuals may respond to specific medications, optimizing treatment plans for efficacy and minimizing adverse reactions. This paradigm shift towards precision medicine is propelling the demand for pharmacogenomic solutions, fostering innovation, and driving advancements in the market.

CHALLENGE: Growing concern related to patient privacy and data access

The pharmaceutical industry faces significant challenges in leveraging pharmacogenomics due to evolving concerns about patient data privacy and restricted data access. Collecting DNA samples for pharmacogenomic studies is now standard practice, yet navigating global regulatory landscapes, especially regarding DNA collection, usage, and export, poses hurdles. In addition, implementing pharmacogenomic findings into clinical practice faces barriers such as limited genetic test use, lack of consensus guidelines, and challenges in demonstrating clinical utility and economic value. The complexity of drug responses due to various factors necessitates exploring emerging opportunities like polygenic risk scores and machine learning for more precise patient stratification. Leveraging large genomic databases presents a promising avenue for drug development, aiding in identifying disease-associated genes, novel drug targets, and supporting ongoing clinical trials.

Global Pharmacogenomics Industry Ecosystem Analysis

The ecosystem of pharmacogenomics consists of end users from academic & research institutes, pharmaceutical & biotechnology companies and contract research organization, pharmacogenomics product & service providers, kits & reagent suppliers, technology providers, data management & analysis providers, regulatory authorities (ensuring compliance and safety), and collaborative networks promoting knowledge sharing and collaboration. These stakeholders interact and collaborate to drive the advancement of pharmacogenomics products, enhance drug discovery processes, and develop new therapeutics.

Pharmacogenomics Market Ecosystem

Sequencing segment held a dominant share in the technology segment in the pharmacogenomics industry

Based on the technology, the pharmacogenomics market has been segmented into sequencing, PCR, microarray, and other technologies. In 2022, sequencing accounted for the largest share of the market. This is attributed to its capacity to offer in-depth insights into individual genetic variations, enabling personalized medicine by optimizing drug selection based on unique genetic profiles. High-throughput sequencing's efficiency and cost-effectiveness contribute significantly to advancing precision medicine within pharmacogenomics.

The personalized medicine segment of pharmacogenomics industry is expected to register fastest growth during the forecast period.

Based on the application of pharmacogenomics, the market has been segmented into personalized medicine, clinical research, and drug discovery & preclinical development. In 2022, personalized medicine accounted for the largest share and is expected to achieve the highest CAGR during the projected period. The key drivers of personalized medicine in the pharmacogenomics market include the ability to tailor drug treatments to individual genetic profiles, enhancing treatment efficacy and minimizing adverse reactions. This patient-centric approach, made possible by pharmacogenomics, is revolutionizing healthcare by optimizing drug selection, dosage, and treatment strategies based on an individual's unique genetic makeup. The growing emphasis on precision medicine is propelling the integration of personalized medicine within the field of pharmacogenomics.

North America accounted for the largest share in pharmacogenomics industry in 2022

Geographically, the pharmacogenomics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America held the dominant share followed by Europe. North America has been a leader in supporting research for the development of innovative genomics and gene therapy. Thus, the development of novel therapies and R&D efforts taken by countries such as US and Canada, and rising number of genomic projects in the region are contributing to the growth of the North America market.

Pharmacogenomics Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key players in the global pharmacogenomics market include Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), BD (US), QIAGEN (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity (US), IQVIA Inc. (US), Mesa Labs, Inc. (US), Medpace (US), MGI Tech Co., Ltd. (China), Takara Bio Inc. (Japan), PacBio (US), New England Biolabs (US), BGI (China), Novogene Co., Ltd. (China), SOPHiA GENETICS (Switzerland), Fios Genomics (UK), Personalis, Inc. (US), BioAI Health Inc. (US), NeoGenomics Laboratories (US), and Macrogen, Inc. (South Korea).

Scope of the Pharmacogenomics Industry

Report Metric

Details

Market Revenue in 2023

$3.5 Billion

Projected Revenue by 2028

$5.8 Billion

Revenue Rate

Poised to Grow at a CAGR of 10.6%

Market Driver

Growing prevalence of chronic and genetic diseases

Market Opportunity

Utilization of genomics in personalized medicine

This report categorizes the pharmacogenomics market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

  • Kits & Reagents
    • Sequencing Kits and Reagents
    • PCR Kits and Reagents
    • Microarray Kits and Reagents
    • Other Kits and Reagents
  • Service

By Technology

  • Sequencing
  • PCR
  • Microarray
  • Other Technologies

By Disease Area

  • Cancer
  • Cardiovascular
  • Neurological Diseases
  • Other Disease Areas

By Application

  • Personalized Medicine
  • Clinical Research
  • Drug discovery & Preclinical Development

By End User

  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America (RoLATAM)
  • Middle East & Africa
    • Middle East
      • GCC
      • Rest of Middle East (RoME)
    • Africa

Recent Developments of Pharmacogenomics Industry:

  • In July 2023, Illumina Inc. partnered with Pillar Biosciences Inc. to globally offer Pillar’s range of oncology assays as an integral part of Illumina’s oncology product portfolio. This partnership will combine various next generation sequencing solutions, creating an unparalleled collection of complementary tools. These advancements in sequencing techniques are poised to elevate the efficiency, precision, and affordability of oncology testing. This collaboration aims to broaden patient access to personalized cancer treatment options.
  • In April 2023, Integrated DNA Technologies, Inc. acquired Archer NGS research assays from Invitae Corporation, which amplifies the xGen NGS lineup, fast-tracking oncology research, notably in discovering new cancer fusions. This addition to IDT’s comprehensive xGen NGS portfolio empowers researchers with unified solutions for uncovering crucial biomarkers, particularly significant cancer fusions.
  • In January 2023, QIAGEN acquired Verogen, a provider of next-generation sequencing (NGS) technologies for application in human identification (HID) and forensic investigation.
  • In October 2021, Roche launched AVENIO Tumor Tissue CGP Kit. It is a research-use-only next-generation sequencing test that provides an end-to-end workflow from DNA extraction and library preparation.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 47)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
           1.2.2 MARKET SEGMENTATION
                    FIGURE 1 PHARMACOGENOMICS MARKET SCOPE
           1.2.3 YEARS CONSIDERED
    1.3 CURRENCY 
    1.4 STAKEHOLDERS 
    1.5 LIMITATIONS 
    1.6 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY (Page No. - 52)
    2.1 RESEARCH DATA 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 3 PHARMACOGENOMICS INDUSTRY: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION 
           2.2.1 BOTTOM-UP APPROACH
                    FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2022)
                    FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
                    FIGURE 6 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2022)
                    2.2.1.1 Insights from primaries
                                FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
           2.2.2 TOP-DOWN APPROACH
                    FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
    2.3 GROWTH FORECAST 
          FIGURE 9 MARKET: CAGR PROJECTIONS
          FIGURE 10 MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 11 DATA TRIANGULATION METHODOLOGY
    2.5 RESEARCH ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 RECESSION IMPACT ANALYSIS 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)
          TABLE 2 US: HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 3 US: HEALTH EXPENDITURE, 2023–2030 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 65)
    FIGURE 12 PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 PHARMACOGENOMICS INDUSTRY, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    FIGURE 14 MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 15 MARKET, BY DISEASE AREA, 2023 VS. 2028 (USD MILLION)
    FIGURE 16 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 17 GEOGRAPHICAL SNAPSHOT OF MARKET
 
4 PREMIUM INSIGHTS (Page No. - 70)
    4.1 PHARMACOGENOMICS MARKET OVERVIEW 
          FIGURE 18 RISING INCIDENCE OF CANCER TO SUPPORT MARKET GROWTH
    4.2 NORTH AMERICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2022) 
          FIGURE 19 KITS & REAGENTS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN PHARMACOGENOMICS INDUSTRY IN 2022
    4.3 MARKET SHARE, BY TECHNOLOGY, 2022 
          FIGURE 20 SEQUENCING SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    4.4 MARKET SHARE, BY APPLICATION, 2022 
          FIGURE 21 PERSONALIZED MEDICINE SEGMENT DOMINATED MARKET IN 2022
    4.5 MARKET SHARE, BY DISEASE AREA, 2022 
          FIGURE 22 CANCER SEGMENT ACCOUNTED FOR LARGEST SHARE OF MARKET IN 2022
    4.6 MARKET SHARE, BY END USER, 2022 
          FIGURE 23 ACADEMIC & RESEARCH INSTITUTES SEGMENT DOMINATED MARKET IN 2022
    4.7 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 24 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 74)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 25 PHARMACOGENOMICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          TABLE 4 PHARMACOGENOMICS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Growing incidence and prevalence of chronic and genetic diseases
                                FIGURE 26 NUMBER OF PEOPLE 65 OR OLDER WITH ALZHEIMER’S DEMENTIA, 2023
                    5.2.1.2 Rising investments and funding to support genomics projects
                    5.2.1.3 Rising incidence of cancer
                                TABLE 5 CANCER INCIDENCE, 2020 VS. 2040
                                TABLE 6 CANCER PGX-RELATED PHARMACOGENES, DRUG PATHWAYS, AND CANCER DRUGS WITH SIDE EFFECTS
                    5.2.1.4 Increasing collaborations and partnerships between key players and research institutes
                                TABLE 7 COLLABORATIONS AND PARTNERSHIPS BETWEEN KEY PLAYERS AND RESEARCH INSTITUTES
                    5.2.1.5 Increasing focus on translational approach to optimize drug development processes
           5.2.2 RESTRAINTS
                    5.2.2.1 Challenges in data integration and interpretation
                    5.2.2.2 Issues related to drug response variabilities
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Use of genomics in specialized/personalized medicine
                    5.2.3.2 AI in pharmacogenomics
                    5.2.3.3 Increasing cost-effectiveness of pharmacogenomics testing
           5.2.4 CHALLENGES
                    5.2.4.1 Ethical and regulatory hurdles
                    5.2.4.2 Growing concerns related to patient privacy and data access
    5.3 TECHNOLOGY ANALYSIS 
           5.3.1 SEQUENCING
                    TABLE 8 COMPARISON OF SANGER SEQUENCING AND NGS
           5.3.2 PCR
                    TABLE 9 COMPARISON OF PCR TECHNOLOGIES
           5.3.3 MICROARRAY
    5.4 VALUE CHAIN ANALYSIS 
          FIGURE 27 PHARMACOGENOMICS MARKET: VALUE CHAIN ANALYSIS
    5.5 SUPPLY CHAIN ANALYSIS 
          FIGURE 28 PHARMACOGENOMICS INDUSTRY: SUPPLY CHAIN ANALYSIS
    5.6 REGULATORY LANDSCAPE 
           5.6.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 13 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.6.2 REGULATORY SCENARIO
                    TABLE 14 PHARMACOGENOMICS MARKET: REGULATORY SCENARIO
    5.7 ECOSYSTEM ANALYSIS 
           5.7.1 PHARMACOGENOMICS PRODUCT VENDORS
                    TABLE 15 PHARMACOGENOMICS PRODUCT VENDORS: ROLE IN ECOSYSTEM
           5.7.2 PHARMACOGENOMICS SERVICE VENDORS
                    TABLE 16 PHARMACOGENOMICS SERVICE VENDORS: ROLE IN ECOSYSTEM
           5.7.3 PHARMACOGENOMICS END USERS
                    TABLE 17 PHARMACOGENOMICS END USERS: ROLE IN ECOSYSTEM
           5.7.4 PHARMACOGENOMICS REGULATORY BODIES
                    TABLE 18 PHARMACOGENOMICS REGULATORY BODIES: ROLE IN ECOSYSTEM
    5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 
          FIGURE 29 REVENUE SHIFT AND NEW REVENUE POCKETS
    5.9 PRICING ANALYSIS 
           5.9.1 AVERAGE SELLING PRICE OF PHARMACOGENOMICS PRODUCTS, BY KEY PLAYER
                    TABLE 19 AVERAGE SELLING PRICE OF PHARMACOGENOMICS PRODUCTS, BY KEY PLAYER (2022)
           5.9.2 AVERAGE SELLING PRICE OF PHARMACOGENOMICS PRODUCTS, BY REGION
                    TABLE 20 AVERAGE SELLING PRICE OF PHARMACOGENOMICS PRODUCTS, BY REGION (2022)
           5.9.3 AVERAGE SELLING PRICE TREND ANALYSIS
                    FIGURE 30 GENOME SEQUENCING PRICING TREND
    5.10 KEY CONFERENCES AND EVENTS IN 2023–2024 
           TABLE 21 PHARMACOGENOMICS MARKET: LIST OF CONFERENCES AND EVENTS
    5.11 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 22 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.11.1 THREAT OF NEW ENTRANTS
           5.11.2 THREAT OF SUBSTITUTES
           5.11.3 BARGAINING POWER OF SUPPLIERS
           5.11.4 BARGAINING POWER OF BUYERS
           5.11.5 INTENSITY OF COMPETITIVE RIVALRY
    5.12 PATENT ANALYSIS 
           FIGURE 31 PATENT APPLICATIONS FOR MARKET, JANUARY 2013–DECEMBER 2023
           TABLE 23 INDICATIVE LIST OF PATENTS IN MARKET
    5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PHARMACOGENOMICS PRODUCTS AND SERVICES
                     TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PHARMACOGENOMICS PRODUCTS AND SERVICES
           5.13.2 BUYING CRITERIA FOR MARKET
                     FIGURE 33 BUYING CRITERIA FOR PHARMACOGENOMICS PRODUCTS
                     TABLE 25 BUYING CRITERIA FOR PHARMACOGENOMICS PRODUCTS AND SERVICES, BY END USER
 
6 PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE (Page No. - 114)
    6.1 INTRODUCTION 
          TABLE 26 PHARMACOGENOMICS INDUSTRY, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
    6.2 KITS & REAGENTS 
          TABLE 27 PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 28 PHARMACOGENOMICS KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 29 NORTH AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 30 EUROPE: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 31 ASIA PACIFIC: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 32 LATIN AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 33 MIDDLE EAST & AFRICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 34 MIDDLE EAST: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.2.1 SEQUENCING KITS & REAGENTS
                    6.2.1.1 Development of new sequencing technologies to drive market
                                TABLE 35 SEQUENCING KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 36 NORTH AMERICA: SEQUENCING KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 37 EUROPE: SEQUENCING KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 38 ASIA PACIFIC: SEQUENCING KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 39 LATIN AMERICA: SEQUENCING KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 40 MIDDLE EAST & AFRICA: SEQUENCING KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 41 MIDDLE EAST: SEQUENCING KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.2.2 PCR KITS & REAGENTS
                    6.2.2.1 Ensures standardized and reliable identification of genetic variants related to drug metabolism
                                TABLE 42 PCR KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 43 NORTH AMERICA: PCR KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 44 EUROPE: PCR KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 45 ASIA PACIFIC: PCR KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 46 LATIN AMERICA: PCR KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 47 MIDDLE EAST & AFRICA: PCR KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 48 MIDDLE EAST: PCR KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.2.3 MICROARRAY KITS & REAGENTS
                    6.2.3.1 Cost-effectiveness and high-throughput capabilities to support adoption
                                TABLE 49 MICROARRAY KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 50 NORTH AMERICA: MICROARRAY KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 51 EUROPE: MICROARRAY KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 52 ASIA PACIFIC: MICROARRAY KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 53 LATIN AMERICA: MICROARRAY KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 54 MIDDLE EAST & AFRICA: MICROARRAY KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 55 MIDDLE EAST: MICROARRAY KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.2.4 OTHER KITS & REAGENTS
                    TABLE 56 OTHER KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 57 NORTH AMERICA: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 58 EUROPE: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 59 ASIA PACIFIC: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 60 LATIN AMERICA: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 61 MIDDLE EAST & AFRICA: OTHER KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 62 MIDDLE EAST: OTHER KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
    6.3 SERVICES 
           6.3.1 SCALABILITY OF CRO SERVICES ALLOWS TAILORED SOLUTIONS
                    TABLE 63 PHARMACOGENOMICS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 64 NORTH AMERICA: PHARMACOGENOMICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 65 EUROPE: PHARMACOGENOMICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 66 ASIA PACIFIC: PHARMACOGENOMICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 67 LATIN AMERICA: PHARMACOGENOMICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 68 MIDDLE EAST & AFRICA: PHARMACOGENOMICS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 69 MIDDLE EAST: PHARMACOGENOMICS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
 
7 PHARMACOGENOMICS MARKET, BY TECHNOLOGY (Page No. - 137)
    7.1 INTRODUCTION 
          TABLE 70 PHARMACOGENOMICS INDUSTRY, BY TECHNOLOGY, 2021–2028 (USD MILLION)
    7.2 SEQUENCING 
           7.2.1 GROWING ADOPTION OF GENETIC TESTING FOR DIAGNOSIS AND TREATMENT TO DRIVE MARKET
                    TABLE 71 SEQUENCING MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 72 NORTH AMERICA: SEQUENCING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 73 EUROPE: SEQUENCING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 74 ASIA PACIFIC: SEQUENCING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 75 LATIN AMERICA: SEQUENCING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 76 MIDDLE EAST & AFRICA: SEQUENCING MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 77 MIDDLE EAST: SEQUENCING MARKET, BY REGION, 2021–2028 (USD MILLION)
    7.3 PCR 
           7.3.1 INCREASED USE OF PCR FOR DRUG AND BIOMARKER DISCOVERY TO PROPEL MARKET
                    TABLE 78 PCR MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 79 NORTH AMERICA: PCR MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 80 EUROPE: PCR MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 81 ASIA PACIFIC: PCR MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 82 LATIN AMERICA: PCR MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 83 MIDDLE EAST & AFRICA: PCR MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 84 MIDDLE EAST: PCR MARKET, BY REGION, 2021–2028 (USD MILLION)
    7.4 MICROARRAY 
           7.4.1 MICROARRAY HELPS UNDERSTAND GENETIC BASIS OF DRUG METABOLISM
                    TABLE 85 MICROARRAY MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 86 NORTH AMERICA: MICROARRAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 87 EUROPE: MICROARRAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 88 ASIA PACIFIC: MICROARRAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 89 LATIN AMERICA: MICROARRAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 90 MIDDLE EAST & AFRICA: MICROARRAY MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 91 MIDDLE EAST: MICROARRAY MARKET, BY REGION, 2021–2028 (USD MILLION)
    7.5 OTHER TECHNOLOGIES 
          TABLE 92 OTHER TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 93 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 94 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 95 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 96 LATIN AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 97 MIDDLE EAST & AFRICA: OTHER TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 98 MIDDLE EAST: OTHER TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION)
 
8 PHARMACOGENOMICS MARKET, BY APPLICATION (Page No. - 153)
    8.1 INTRODUCTION 
          TABLE 99 PHARMACOGENOMICS INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
    8.2 PERSONALIZED MEDICINE 
           8.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
                    TABLE 100 PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 101 NORTH AMERICA: MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 102 EUROPE: MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 103 ASIA PACIFIC: MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 104 LATIN AMERICA: MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 105 MIDDLE EAST & AFRICA: MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 106 MIDDLE EAST: MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021–2028 (USD MILLION)
    8.3 CLINICAL RESEARCH 
           8.3.1 GROWING NUMBER OF CLINICAL TRIALS FOR PHARMACOGENOMICS TO DRIVE MARKET
                    TABLE 107 PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 108 NORTH AMERICA: MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 109 EUROPE: MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 110 ASIA PACIFIC: MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 111 LATIN AMERICA: MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 112 MIDDLE EAST & AFRICA: MARKET FOR CLINICAL RESEARCH, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 113 MIDDLE EAST: MARKET FOR CLINICAL RESEARCH, BY REGION, 2021–2028 (USD MILLION)
    8.4 DRUG DISCOVERY & PRECLINICAL DEVELOPMENT 
           8.4.1 INCREASING APPLICATIONS OF PHARMACOGENOMICS IN DRUG DISCOVERY AND DEVELOPMENT TO SUPPORT MARKET GROWTH
                    TABLE 114 PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 115 NORTH AMERICA: MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 116 EUROPE: MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 117 ASIA PACIFIC: MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 118 LATIN AMERICA: MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 119 MIDDLE EAST & AFRICA: MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 120 MIDDLE EAST: MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION)
 
9 PHARMACOGENOMICS MARKET, BY DISEASE AREA (Page No. - 166)
    9.1 INTRODUCTION 
          TABLE 121 PHARMACOGENOMICS INDUSTRY, BY DISEASE AREA, 2021–2028 (USD MILLION)
    9.2 CANCER 
           9.2.1 INCREASING PREVALENCE OF CANCER TO DRIVE MARKET
                    TABLE 122 PHARMACOGENOMICS MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 123 NORTH AMERICA: MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 124 EUROPE: MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 125 ASIA PACIFIC: MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 126 LATIN AMERICA: MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 127 MIDDLE EAST & AFRICA: MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 128 MIDDLE EAST: MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION)
    9.3 CARDIOVASCULAR DISEASE 
           9.3.1 RISING DEMAND FOR PRECISION MEDICINE TO SUPPORT MARKET GROWTH
                    TABLE 129 PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 130 NORTH AMERICA: MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 131 EUROPE: MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 132 ASIA PACIFIC: MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 133 LATIN AMERICA: MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 134 MIDDLE EAST & AFRICA: MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 135 MIDDLE EAST: MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2021–2028 (USD MILLION)
    9.4 NEUROLOGICAL DISORDERS 
           9.4.1 GROWING DEMAND FOR PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH
                    TABLE 136 PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 137 NORTH AMERICA: MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 138 EUROPE:  MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 139 ASIA PACIFIC: MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 140 LATIN AMERICA: MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 141 MIDDLE EAST & AFRICA: MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 142 MIDDLE EAST: MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
    9.5 OTHER DISEASE AREAS 
          TABLE 143 PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 144 NORTH AMERICA: MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 145 EUROPE: MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 146 ASIA PACIFIC: MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 147 LATIN AMERICA: MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 148 MIDDLE EAST & AFRICA: MARKET FOR OTHER DISEASE AREAS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 149 MIDDLE EAST: MARKET FOR OTHER DISEASE AREAS, BY REGION, 2021–2028 (USD MILLION)
 
10 PHARMACOGENOMICS MARKET, BY END USER (Page No. - 182)
     10.1 INTRODUCTION 
             TABLE 150 PHARMACOGENOMICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     10.2 ACADEMIC & RESEARCH INSTITUTES 
             10.2.1 INCREASING RESEARCH ACTIVITIES AND FUNDING TO DRIVE GROWTH
                        TABLE 151 PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 152 NORTH AMERICA: PHARMACOGENOMICS INDUSTRY FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 153 EUROPE: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 154 ASIA PACIFIC: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 155 LATIN AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 156 MIDDLE EAST & AFRICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 157 MIDDLE EAST: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
     10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
             10.3.1 GROWING STRATEGIC ALLIANCES FOR DRUG DEVELOPMENT AND PERSONALIZED MEDICINE TO PROPEL MARKET
                        TABLE 158 PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 159 NORTH AMERICA: PHARMACOGENOMICS INDUSTRY FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 160 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 161 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 162 LATIN AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 163 MIDDLE EAST & AFRICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 164 MIDDLE EAST: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
     10.4 CONTRACT RESEARCH ORGANIZATIONS 
             10.4.1 INCREASING OUTSOURCING TREND IN GENOMICS FIELD TO PROPEL MARKET
                        TABLE 165 PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 166 NORTH AMERICA: PHARMACOGENOMICS INDUSTRY FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 167 EUROPE: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 168 ASIA PACIFIC: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 169 LATIN AMERICA: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 170 MIDDLE EAST & AFRICA: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 171 MIDDLE EAST: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
 
11 PHARMACOGENOMICS MARKET, BY REGION (Page No. - 195)
     11.1 INTRODUCTION 
             TABLE 172 PHARMACOGENOMICS INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     11.2 NORTH AMERICA 
             FIGURE 34 NORTH AMERICA: PHARMACOGENOMICS MARKET SNAPSHOT
             TABLE 173 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 174 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 175 NORTH AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 176 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 177 NORTH AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 178 NORTH AMERICA: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
             TABLE 179 NORTH AMERICA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.1 US
                        11.2.1.1 US dominates North American pharmacogenomics market
                                      TABLE 180 US: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 181 US: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 182 US: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 183 US: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 184 US: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 185 US: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 Growing research activities in genomics field to drive market
                                      TABLE 186 CANADA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 187 CANADA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 188 CANADA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 189 CANADA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 190 CANADA: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 191 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.3 RECESSION IMPACT ON NORTH AMERICAN PHARMACOGENOMICS MARKET
     11.3 EUROPE 
             TABLE 192 EUROPE: PHARMACOGENOMICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 193 EUROPE: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 194 EUROPE: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 195 EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 196 EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 197 EUROPE: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
             TABLE 198 EUROPE: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.1 GERMANY
                        11.3.1.1 Growing strategic alliances among industry players and research institutes to support market growth
                                      TABLE 199 GERMANY: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 200 GERMANY: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 201 GERMANY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 202 GERMANY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 203 GERMANY: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 204 GERMANY: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.2 UK
                        11.3.2.1 Increasing government funding for genomics projects to propel market
                                      TABLE 205 UK: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 206 UK: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 207 UK: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 208 UK: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 209 UK: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 210 UK: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.3 FRANCE
                        11.3.3.1 Increasing government initiatives to boost market growth
                                      TABLE 211 FRANCE: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 212 FRANCE: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 213 FRANCE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 214 FRANCE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 215 FRANCE: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 216 FRANCE: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.4 ITALY
                        11.3.4.1 Favorable funding programs to support market growth
                                      TABLE 217 ITALY: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 218 ITALY: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 219 ITALY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 220 ITALY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 221 ITALY: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 222 ITALY: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.5 SPAIN
                        11.3.5.1 Government funding for research in pharmacogenomics and precision medicine to drive market
                                      TABLE 223 SPAIN: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 224 SPAIN: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 225 SPAIN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 226 SPAIN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 227 SPAIN: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 228 SPAIN: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.6 REST OF EUROPE
                        TABLE 229 REST OF EUROPE: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 230 REST OF EUROPE: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 231 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 232 REST OF EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 233 REST OF EUROPE: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                        TABLE 234 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.7 RECESSION IMPACT ON EUROPEAN PHARMACOGENOMICS MARKET
     11.4 ASIA PACIFIC 
             FIGURE 35 ASIA PACIFIC: PHARMACOGENOMICS MARKET SNAPSHOT
             TABLE 235 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 236 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 237 ASIA PACIFIC: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 238 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 239 ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 240 ASIA PACIFIC: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
             TABLE 241 ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.1 CHINA
                        11.4.1.1 Increasing research and development spending to support market growth
                                      TABLE 242 CHINA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 243 CHINA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 244 CHINA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 245 CHINA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 246 CHINA: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 247 CHINA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.2 JAPAN
                        11.4.2.1 Growing focus on development of new pharmacogenomic services to drive market
                                      TABLE 248 JAPAN: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 249 JAPAN: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 250 JAPAN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 251 JAPAN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 252 JAPAN: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 253 JAPAN: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Growing prevalence of chronic diseases to drive market
                                      TABLE 254 INDIA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 255 INDIA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 256 INDIA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 257 INDIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 258 INDIA: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 259 INDIA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.4 AUSTRALIA
                        11.4.4.1 Increase in research activities to propel market
                                      TABLE 260 AUSTRALIA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 261 AUSTRALIA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 262 AUSTRALIA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 263 AUSTRALIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 264 AUSTRALIA: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 265 AUSTRALIA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.5 SOUTH KOREA
                        11.4.5.1 Increasing investments in genomics research to drive market
                                      TABLE 266 SOUTH KOREA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 267 SOUTH KOREA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 268 SOUTH KOREA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 269 SOUTH KOREA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 270 SOUTH KOREA: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 271 SOUTH KOREA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.6 REST OF ASIA PACIFIC
                        TABLE 272 REST OF ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 273 REST OF ASIA PACIFIC: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 274 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 275 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 276 REST OF ASIA PACIFIC: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                        TABLE 277 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.7 RECESSION IMPACT ON ASIA PACIFIC PHARMACOGENOMICS MARKET
     11.5 LATIN AMERICA 
             TABLE 278 LATIN AMERICA: PHARMACOGENOMICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 279 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 280 LATIN AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 281 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 282 LATIN AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 283 LATIN AMERICA: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
             TABLE 284 LATIN AMERICA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.1 BRAZIL
                        11.5.1.1 Increasing investments in biopharmaceutical research to propel market
                                      TABLE 285 BRAZIL: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 286 BRAZIL: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 287 BRAZIL: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 288 BRAZIL: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 289 BRAZIL: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 290 BRAZIL: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.2 MEXICO
                        11.5.2.1 Increasing genomics research activities to drive market
                                      TABLE 291 MEXICO: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 292 MEXICO: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 293 MEXICO: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 294 MEXICO: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 295 MEXICO: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 296 MEXICO: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.3 REST OF LATIN AMERICA
                        TABLE 297 REST OF LATIN AMERICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 298 REST OF LATIN AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 299 REST OF LATIN AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 300 REST OF LATIN AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 301 REST OF LATIN AMERICA: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                        TABLE 302 REST OF LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.4 RECESSION IMPACT ON LATIN AMERICAN PHARMACOGENOMICS MARKET
     11.6 MIDDLE EAST & AFRICA 
             TABLE 303 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
             TABLE 304 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 305 MIDDLE EAST & AFRICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 306 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 307 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 308 MIDDLE EAST & AFRICA: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
             TABLE 309 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.6.1 MIDDLE EAST
                        TABLE 310 MIDDLE EAST: PHARMACOGENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 311 MIDDLE EAST: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 312 MIDDLE EAST: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 313 MIDDLE EAST: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 314 MIDDLE EAST: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 315 MIDDLE EAST: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                        TABLE 316 MIDDLE EAST: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
                        11.6.1.1 GCC countries
                                     11.6.1.1.1 Increasing government initiatives for pharmacogenomics to propel market
                                                      TABLE 317 GCC COUNTRIES: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                                      TABLE 318 GCC COUNTRIES: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                                      TABLE 319 GCC COUNTRIES: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                                      TABLE 320 GCC COUNTRIES: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                                      TABLE 321 GCC COUNTRIES: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                                      TABLE 322 GCC COUNTRIES: MARKET, BY END USER, 2021–2028 (USD MILLION)
                        11.6.1.2 Rest of Middle East
                                      TABLE 323 REST OF MIDDLE EAST: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 324 REST OF MIDDLE EAST: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 325 REST OF MIDDLE EAST: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 326 REST OF MIDDLE EAST: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 327 REST OF MIDDLE EAST: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 328 REST OF MIDDLE EAST: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.6.2 AFRICA
                        11.6.2.1 Growing prevalence of HIV & cancer to drive market
                                      TABLE 329 AFRICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 330 AFRICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 331 AFRICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 332 AFRICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 333 AFRICA: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 334 AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.6.3 RECESSION IMPACT ON MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET
 
12 COMPETITIVE LANDSCAPE (Page No. - 290)
     12.1 OVERVIEW 
     12.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             FIGURE 36 PHARMACOGENOMICS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
     12.3 REVENUE SHARE ANALYSIS 
             FIGURE 37 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN PHARMACOGENOMICS INDUSTRY, 2018–2022 (USD MILLION)
     12.4 MARKET SHARE ANALYSIS 
             FIGURE 38 PHARMACOGENOMICS INDUSTRY SHARE, BY KEY PLAYER (2022)
             TABLE 335 PHARMACOGENOMICS INDUSTRY: INTENSITY OF COMPETITIVE RIVALRY
     12.5 COMPANY EVALUATION MATRIX 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 39 PHARMACOGENOMICS INDUSTRY: COMPANY EVALUATION MATRIX (2022)
             12.5.5 COMPANY FOOTPRINT
                        TABLE 336 PRODUCT & SERVICE FOOTPRINT
                        TABLE 337 REGIONAL FOOTPRINT
     12.6 STARTUP/SME EVALUATION MATRIX 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 RESPONSIVE COMPANIES
             12.6.3 DYNAMIC COMPANIES
             12.6.4 STARTING BLOCKS
                        FIGURE 40 PHARMACOGENOMICS INDUSTRY: STARTUP/SME EVALUATION MATRIX (2022)
     12.7 COMPETITIVE BENCHMARKING 
             TABLE 338 PHARMACOGENOMICS INDUSTRY: DETAILED LIST OF KEY STARTUPS/SMES
             TABLE 339 PHARMACOGENOMICS INDUSTRY: PRODUCT & SERVICE AND REGIONAL FOOTPRINT OF KEY STARTUPS/SMES
     12.8 COMPETITIVE SCENARIO 
             TABLE 340 PHARMACOGENOMICS INDUSTRY: PRODUCT & SERVICE LAUNCHES, JANUARY 2020–DECEMBER 2023
             TABLE 341 PHARMACOGENOMICS INDUSTRY: DEALS, JANUARY 2020−DECEMBER 2023
             TABLE 342 PHARMACOGENOMICS INDUSTRY: OTHER DEVELOPMENTS, JANUARY 2020− DECEMBER 2023
 
13 COMPANY PROFILES (Page No. - 308)
     13.1 KEY PLAYERS 
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
             13.1.1 ILLUMINA, INC.
                        TABLE 343 ILLUMINA, INC.: BUSINESS OVERVIEW
                        FIGURE 41 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)
             13.1.2 THERMO FISHER SCIENTIFIC INC.
                        TABLE 344 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
                        FIGURE 42 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
             13.1.3 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 345 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
                        FIGURE 43 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
             13.1.4 QIAGEN
                        TABLE 346 QIAGEN: BUSINESS OVERVIEW
                        FIGURE 44 QIAGEN: COMPANY SNAPSHOT (2022)
             13.1.5 DANAHER CORPORATION
                        TABLE 347 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
             13.1.6 LABORATORY CORPORATION OF AMERICA HOLDINGS
                        TABLE 348 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
                        FIGURE 46 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022)
             13.1.7 EUROFINS SCIENTIFIC
                        TABLE 349 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
                        FIGURE 47 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)
             13.1.8 CHARLES RIVER LABORATORIES
                        TABLE 350 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 48 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2022)
             13.1.9 BIO-RAD LABORATORIES, INC.
                        TABLE 351 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 49 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
             13.1.10 AGILENT TECHNOLOGIES, INC.
                        TABLE 352 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
                        FIGURE 50 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
             13.1.11 BECTON, DICKINSON AND COMPANY
                        TABLE 353 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 51 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
             13.1.12 REVVITY
                        TABLE 354 REVVITY: BUSINESS OVERVIEW
                        FIGURE 52 REVVITY: COMPANY SNAPSHOT (2022)
             13.1.13 IQVIA, INC.
                        TABLE 355 IQVIA, INC.: BUSINESS OVERVIEW
                        FIGURE 53 IQVIA, INC.: COMPANY SNAPSHOT (2022)
             13.1.14 MESA LABS, INC.
                        TABLE 356 MESA LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 54 MESA LABS, INC.: COMPANY SNAPSHOT (2022)
             13.1.15 MEDPACE, INC.
                        TABLE 357 MEDPACE, INC.: BUSINESS OVERVIEW
                        FIGURE 55 MEDPACE, INC.: COMPANY SNAPSHOT (2022)
             13.1.16 MGI TECH CO., LTD.
                        TABLE 358 MGI TECH CO., LTD.: BUSINESS OVERVIEW
                        FIGURE 56 MGI TECH CO., LTD.: COMPANY SNAPSHOT (2022)
     13.2 OTHER PLAYERS 
             13.2.1 PACBIO
                        TABLE 359 PACBIO: COMPANY OVERVIEW
             13.2.2 TAKARA BIO INC.
                        TABLE 360 TAKARA BIO INC.: COMPANY OVERVIEW
             13.2.3 NEW ENGLAND BIOLABS
                        TABLE 361 NEW ENGLAND BIOLABS: COMPANY OVERVIEW
             13.2.4 BGI
                        TABLE 362 BGI: COMPANY OVERVIEW
             13.2.5 NOVOGENE CO., LTD.
                        TABLE 363 NOVOGENE CO., LTD.: COMPANY OVERVIEW
             13.2.6 SOPHIA GENETICS
                        TABLE 364 SOPHIA GENETICS: COMPANY OVERVIEW
             13.2.7 FIOS GENOMICS
                        TABLE 365 FIOS GENOMICS: COMPANY OVERVIEW
             13.2.8 PERSONALIS, INC.
                        TABLE 366 PERSONALIS, INC.: COMPANY OVERVIEW
             13.2.9 NEOGENOMICS LABORATORIES
                        TABLE 367 NEOGENOMICS LABORATORIES: COMPANY OVERVIEW
             13.2.10 BIOAI HEALTH INC.
                        TABLE 368 BIOAI HEALTH INC.: COMPANY OVERVIEW
             13.2.11 MACROGEN, INC.
                        TABLE 369 MACROGEN, INC.: COMPANY OVERVIEW
 
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
 
14 APPENDIX (Page No. - 387)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global pharmacogenomics market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the pharmacogenomics market. The secondary sources used for this study include Centers for Disease Control and Prevention (CDC), United States Food and Drug Administration (US FDA), World Health Organization (WHO), American Cancer Society, National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), International Chromosome and Genome Society (ICGS), International Mammalian Genome Society (IMGS), International Agency for Research on Cancer (IARC), National Human Genome Research Institute (NHGRI), Centers for Common Disease Genomics (CCDG), Genome Canada, European Society of Human Genetics (ESHG), Genomics England, and Beijing Institute of Genomics. Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements), business magazines and research journals, press releases, and trade, business, and professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global pharmacogenomics market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (personnel from pharmaceutical & biopharmaceutical and biotechnology companies, CROs, and academic & research institutes) and supply side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others, from Tier 1 and Tier 2 companies engaged in offering products) across five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Approximately 70% of primary interviews were conducted with supply-side representatives, while demand-side participants accounted for the remaining share. This preliminary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

Pharmacogenomics Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the pharmacogenomics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Bottom-up Approach

  • The key players in the industry and market have been identified through extensive secondary research.
  • The revenues generated from the pharmacogenomics business of leading players have been determined through primary and secondary research.

All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Pharmacogenomics Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Top-down Approach

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

Pharmacogenomics Market Size, and Share

Data Triangulation

To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Pharmacogenomics, also known as pharmacogenetics, is a specialized field within genomic medicine that utilizes an individual’s genetic information to personalize the selection and administration of drugs in their medical treatment. It aims to optimize therapeutic outcomes by tailoring medication choices based on a patient’s unique genetic makeup.

The market scope of this report is restricted to kits & reagents and services provided by pharmacogenomics product & service providers (such as Illumina, Thermo Fisher Scientific, and PacBio) and pharmacogenomics services provided by CROs for applications in drug discovery and preclinical, clinical, and personalized medicine development.

Stakeholders

  • Academic & Research Institutes
  • Biotechnology Companies
  • Pharmaceutical & Biopharmaceutical Companies
  • Contract Research Organizations (CROs)
  • Genomics Product & Service Providers
  • Market Research & Consulting Firms
  • Venture Capitalists & Investors
  • Government Associations
  • Manufacturers of Pharmacogenomics Testing Products

Report Objectives

  • To define, describe, and forecast the global pharmacogenomics market based on product & service, technology, application, disease area, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the global pharmacogenomics market and comprehensively analyze their core competencies2 and market shares
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations in the pharmacogenomics market
  • To benchmark players in the pharmacogenomics market using the “Company Evaluation Matrix” framework, which analyzes market players based on various parameters, including product portfolio, geographic reach, and market share

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographical Analysis

  • Further breakdown of the Rest of Europe pharmacogenomics market, by country
  • Further breakdown of the Rest of Asia Pacific pharmacogenomics market, by country
  • Further breakdown of the Rest of Latin America pharmacogenomics market, by country

Company Information

  • Detailed analysis and profiling of additional market players (up to five)

Segment Analysis

  • Further breakdown of the other technologies and other kits & regents into subsegments
  • Cross-segment analysis
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization
Report Code
BT 8937
Published ON
Feb, 2024
REQUEST FREE SAMPLE REPORT
Choose License Type
BUY NOW
Inquire Before Buying
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Pharmacogenomics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback